Find uplifting stories about heroes, innovations, and solutions
8435 results for "als treatment"
A newly approved ALS treatment can now target specific genetic causes of the disease, offering hope to patients with Lou Gehrig's disease. The FDA fast-tracked the therapy, marking a significant breakthrough in personalized medicine for neurological conditions.
An experimental therapy targeting the immune system could slow ALS progression for thousands of patients. Temple Health researchers are testing Coya 302, offering new hope beyond current limited treatments.
Researchers in Belgium discovered how a common molecule called spermidine can restore damaged neurons in ALS, offering fresh hope for treating this devastating disease. The breakthrough could guide the development of new therapies for patients with amyotrophic lateral sclerosis.
A promising new treatment for ALS has entered human trials across multiple countries, offering hope to patients by targeting a protein crucial for nerve-muscle communication. The therapy aims to restore function in most ALS patients through a novel genetic approach.
A University of Missouri researcher found a way to deliver healing molecules past the brain's protective barrier, improving ALS symptoms in mice. The breakthrough could lead to human trials that might one day prevent the disease before symptoms start.
A new treatment for ALS significantly extended patient survival and delayed the need for breathing support in a Phase 2 trial, offering rare evidence of disease modification. AP-101 works by clearing toxic protein clumps that damage nerve cells in people with the fatal disease.
After decades of slow progress, ALS researchers at VCU Health say they're more optimistic about finding a cure than at any point in history. The Richmond team is combining new FDA-approved treatments with cutting-edge research to extend lives and find solutions.
Jeff Vierstra lost his mother and two sisters to a deadly genetic disease, but an experimental treatment may be preventing him from developing ALS for the first time in his family's history. After three years of spinal infusions targeting his mutated gene, the 41-year-old shows no signs of the disease.
A breakthrough drug called AMX0035 is giving hope to 35,000 Americans living with ALS by significantly slowing the disease's progression. Research advances at Columbia's ALS Center are helping patients live longer with better quality of life. ##
A promising oral therapy for ALS is moving toward Canadian approval after the company received regulatory clearance to file by December. Clinical trial data showed the treatment may extend survival by nearly 15 months when started early.
The U.S. just approved the largest federal ALS research budget in history at $315 million. New treatments targeting the disease's root causes are showing real promise for the first time.
Scientists in West Michigan are creating breakthrough treatments that attack the root causes of ALS rather than just managing symptoms. Their work focuses on fixing the genetic mutations that trigger this devastating disease.
Researchers have successfully grown specialized brain cells that die in ALS and get damaged in spinal injuries, opening new doors for treatment. For the first time, scientists can reliably create these rare corticospinal neurons in the lab.
Researchers developed an AI model that predicts how ALS affects the nervous system, potentially reducing the need for animal testing while speeding up treatment discoveries. The breakthrough combines computer simulations with real-world biology to guide more precise research.
Scientists at Stanford just received $13 million to use cutting-edge artificial intelligence to uncover the hidden genetic causes of ALS, a devastating disease that currently has no cure. They've already discovered one new gene and hope to find many more targets for future treatments.
A promising ALS treatment has enrolled its first patient in a major clinical trial that could slow disease progression. The drug showed encouraging results in early-stage patients during previous testing.
A groundbreaking ALS treatment has enrolled its first patient in a major clinical trial that could help slow disease progression in early-stage patients. The study follows encouraging results showing the drug helped preserve speech and breathing function in rapid-decline patients.
Researchers at Mayo Clinic are turning groundbreaking genetic discoveries into real treatments for ALS and dementia patients. New diagnostic tools, AI-powered voice technology, and targeted therapies are giving families fresh reasons for hope.
Former NFL running back Chris Johnson, diagnosed with ALS at 39, is defying his initial prognosis through experimental treatments and clinical trials. His courage and determination to fight the disease are helping advance research that could benefit thousands.
Amanda Sifford's lung capacity dropped to 48 percent before she received tofersen, a new drug that stopped her ALS decline and reversed her symptoms. Nearly 20 percent of patients in a three-year study showed improvement in breathing, strength, and function.
Showing 20 of 8435